Oura’s Confidential IPO Marks a New Phase for Smart Rings
ŌURA, maker of the Oura Ring, has confidentially filed with the US Securities and Exchange Commission for an initial public offering, signaling a major milestone for the smart ring market. The filing follows a substantial Series E financing round completed in October 2025 that raised USD 900 million (approx. RM4.14 billion) and placed the company’s valuation at about USD 11 billion (approx. RM50.6 billion). The IPO will be led by a syndicate including Goldman Sachs, Morgan Stanley, JPMorgan, Allen & Co. and Jefferies, highlighting strong institutional interest in health wearables IPO opportunities. While details such as share count, pricing, and exact timing remain undisclosed, Oura has indicated that the offering will proceed once regulatory review and market conditions align. The move positions Oura as one of the highest-profile players turning investor enthusiasm for continuous biometric tracking into public-market capital.
From Niche Gadget to Mainstream Smart Ring Market Leader
Oura’s IPO plans arrive as fitness tracking rings are shifting from early-adopter gadgets to mainstream health tools. The company has sold 5.5 million rings to date, more than doubling from 2.5 million units in mid-2024, and reports that it is on track to surpass five million paid members this quarter. Its rings sync with smartphone apps to monitor sleep, heart rate, stress and overall readiness, offering a lower-profile alternative to bulky smartwatches and fitness trackers. Revenue reached more than USD 500 million (approx. RM2.3 billion) in 2024, doubling from the prior year, and Oura has projected further acceleration, with expectations of USD 1.5 billion (approx. RM6.9 billion) in 2026 revenue. This growth underscores how smart rings now occupy a distinct niche within health wearables, appealing to consumers who want round-the-clock biometrics without the aesthetic trade-offs of wrist devices.
Strategic Medtech Partnerships Push Oura Beyond Consumer Wellness
Although Oura Ring is categorized as a consumer wellness product, recent partnerships show how the company is edging closer to the medtech ecosystem. Dexcom invested USD 75 million (approx. RM345 million) in ŌURA in November 2024, forming a collaboration to integrate continuous glucose monitoring data with Oura’s metrics on sleep, cardiovascular trends and stress. The goal is to help users see how lifestyle factors affect glucose variability in real time, expanding the utility of fitness tracking rings for people managing metabolic health. Oura has also partnered with femtech firm Mira to give ring users access to lab-grade hormone testing data, strengthening its role in women’s health and fertility tracking. These alliances deepen Oura’s data moat, enhance subscription value and position the company as a bridge between consumer wearables and clinically relevant insights, a narrative likely to resonate with IPO investors.
Competitive Pressures from Big Tech and New Ring Rivals
Oura’s public ambitions unfold against intensifying competition in the smart ring market and broader wearables space. The company directly challenges established smartwatch players such as Apple and Samsung, both of which are exploring new form factors for health wearables. Samsung introduced its own ring-style device two years ago, and Apple is working on AI-powered wearable concepts, raising the stakes for data accuracy, design, and ecosystem integration. At the same time, smaller entrants are developing fitness tracking rings that promise differentiated features or lower prices, potentially squeezing margins. Despite these pressures, Oura’s early-mover advantage, strong brand recognition and growing subscriber base provide meaningful defensibility. The IPO will test whether public-market investors believe the company can maintain that edge as big tech converges on ring-based health tracking and consumers gain more options than ever for unobtrusive biometric monitoring.
What Oura’s IPO Signals for the Future of Health Wearables
Oura’s move toward a public listing signals broader investor confidence in health wearables IPO candidates that combine hardware, software and recurring revenue. With subscription memberships growing fourfold over two years and revenue more than doubling between 2023 and 2024, Oura exemplifies how continuous biometric tracking can underpin a compelling growth story. If the offering performs well, it could encourage more startups and medtech firms to pursue fitness tracking ring strategies or spin out specialized platforms for sleep, stress and metabolic monitoring. It may also accelerate standards for data interoperability, as seen in Oura’s partnerships with Dexcom and Mira. Ultimately, the success of the Oura Ring IPO will help determine whether smart rings remain a fast-growing niche or evolve into a core category of everyday health infrastructure, sitting alongside smartphones and smartwatches as primary interfaces for personal wellness data.